. Scientific Frontline: Genetic Glaucoma Test Predicts Risk Decades Early

Tuesday, November 17, 2026

Genetic Glaucoma Test Predicts Risk Decades Early

Close-up of a brown female eye.
Photo Credit: Takwa Abdo

Scientific Frontline: Extended "At a Glance" Summary
: Polygenic Risk Scoring for Glaucoma

The Core Concept: A new genetic screening test utilizes polygenic risk scoring to identify an individual's susceptibility to developing glaucoma and the likelihood of severe disease progression up to 25 years before clinical symptoms appear.

Key Distinction/Mechanism: Unlike traditional screenings that rely on detecting early vision loss or elevated intraocular pressure, this test analyzes genetic data to predict baseline risk. In individuals of European ancestry, those in the highest 10 percent of genetic risk are ten times more likely to develop the disease, allowing for targeted intervention before irreversible optic nerve damage occurs.

Origin/History: Published in Ophthalmology in November 2026, the study was led by researchers at Flinders University and QIMR Berghofer, who validated the test's clinical utility using the Australian and New Zealand Registry of Advanced Glaucoma.

Major Frameworks/Components:

  • Polygenic Risk Score (PRS): A statistical calculation based on multiple genetic variations to evaluate the cumulative genetic risk of developing a complex disease.
  • Disease Progression Forecasting: The test predicts long-term clinical trajectories, identifying patients who are highly likely to require surgical intervention (e.g., nearly 25 percent of highest-risk individuals required surgery by age 80, compared to zero in the lowest-risk group).
  • Clinical Integration: The genetic data is designed to supplement standard clinical assessments, guiding targeted screening and personalized monitoring protocols.

Branches of Science: Statistical Genetics, Ophthalmic Genetics, Ophthalmology, Preventive Medicine.

Future Application: Integrating the polygenic risk score into standard clinical care to create personalized, early screening programs for glaucoma, thereby reducing the incidence of irreversible blindness through proactive management.

Why It Matters: Glaucoma is the leading global cause of irreversible blindness and often remains asymptomatic until permanent damage has occurred. Early detection through genetic risk profiling gives clinicians a crucial window to monitor and treat the condition before any vision is lost.

Glaucoma is the leading cause of irreversible blindness worldwide, yet it often develops without symptoms. By the time many people notice changes to their vision, permanent damage has already occurred, leaving about half of all cases undiagnosed. New research led by Flinders University and QIMR Berghofer suggests a genetic test could help identify people most at risk long before symptoms appear, giving doctors a better chance to monitor patients, start treatment earlier, and help prevent avoidable blindness.

Published in Ophthalmology, the study found that genetic information can help predict not only who is most likely to develop glaucoma, but also whose disease is more likely to progress and require surgery.

Flinders University leads the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG), which was used to validate the clinical value of the new test in Australian patients.

Senior author Jamie Craig, co-director of the Flinders Health and Medical Research Institute (FHMRI) Eye and Vision group, says the research could help doctors identify people at greatest risk before vision is lost.

“One of the biggest challenges with glaucoma is that many people don’t know they have it until permanent damage has already occurred,” says Craig.

“Many patients are shocked to learn they have glaucoma because they haven’t noticed any change in their vision. Once vision is lost, we can’t restore it, which is why early detection is so important.”

The study found that people in the highest genetic risk group developed glaucoma up to 25 years earlier than those in the lowest risk group. Researchers also found the test could help predict which patients were more likely to experience disease progression and require surgery.

“Genetic information could help us identify who may benefit from earlier screening, closer monitoring, and timely treatment to protect their vision,” says Craig.

Lead author Professor Stuart MacGregor, head of QIMR Berghofer’s Statistical Genetics Laboratory, says the test represents a major advance in glaucoma risk prediction.

“Among individuals of European ancestry, those in the highest 10 percent for genetic risk were ten times more likely to develop glaucoma compared to the baseline population average. Our earlier test identified about a fourfold increase in risk,” says MacGregor.

“To our knowledge, this is the strongest genetic risk prediction reported for any common complex disease.”

Importantly for patients and clinicians, the test also helped predict disease severity. In a long-term study of people with suspected or early glaucoma, almost one in four people in the highest-risk group required glaucoma surgery by age 80, compared with none in the lowest-risk group.

The researchers hope the approach will ultimately help reduce the number of people who lose vision from glaucoma by identifying high-risk individuals before irreversible damage occurs. Further studies are planned to investigate how the test could best be incorporated into glaucoma screening and care.

Funding: Acknowledgments: This work was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (nos. 1107098, 1116360, 1116495, 1023911, and 1150144), the Ophthalmic Research Institute of Australia, and the BrightFocus Foundation. SM, JEC, DAM, PG, and AWH are supported by NHMRC grants (Fellowship/Investigator/Program); OMS by the Snow Medical Research Foundation (grant no. PF2019-040); and DAM by Glaucoma Australia and Telethon.

Published in journal: Ophthalmology

Title: Step change in glaucoma polygenic risk score performance enables clinical utility

Authors: Stuart MacGregor, Guiyan Ni, Mathias Seviiri, Antonia Kolovos, Ngoc Quynh Le, Mark M. Hassall, Josh Schmidt, Puya Gharahkhani, Victoria Tang, Emmanuelle Souzeau, Ayub Qassim, Priyanka Nandakumar, Suyash Shringarpure, Julie M. Granka, Jessica N. Cooke Bailey, Tin Aung, John Landers, Stuart L. Graham, Paul R. Healey, Anthony P. Khawaja, Louis R. Pasquale, Janey L. Wiggs, Joan O'Brien, Robert N. Weinreb, Colin E. Willoughby, Andrew Lotery, Paul Mitchell, David A. Mackey, Alex W. Hewitt, Nick Haan, Owen M. Siggs, and Jamie E. Craig

Source/Credit: Flinders University

Edited by: Scientific Frontline

Reference Number: gen111726_01

Privacy Policy | Terms of Service | Contact Us

Featured Article

What Is: The Minimal Genome and Synthetic Evolution

Scientific Frontline: Extended "At a Glance" Summary : The Minimal Genome and Synthetic Evolution The Core Concept : Researchers h...

Top Viewed Articles